DNL ETF

Designed to provide broad exposure to the World ETFs category of the market, the WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) is a smart beta exchange traded fund launched on 06/16/2006.

Launched on 06/16/2006, the WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) is a smart beta exchange traded fund offering broad exposure to the World ETFs category of the market.

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the outcome of a recent successful meeting with the Center for Drug Evaluation and Research (CDER) division of the U.S. Food and Drug Administration (FDA) providing a path to filing a biologics license application (BLA) for accelerated approval and subsequent conversion to full approval for tividenofusp alfa (DNL310) for the treatment of MPS II (Hunter syndrome). Agreement was reached that cerebrospinal fluid heparan sulfate (CSF HS) is reasonably likely to predict clinical benefit and can be used as a surrogate endpoint to support accelerated approval for tividenofusp alfa in MPS II. Based on discussions with CDER, Denali will include preclinical and clinical data on biomarkers (CSF HS and neurofilament light (NfL)) and safety in the BLA for tividenofusp alfa as a treatment of MPS II and intends to submit the BLA under the accelerated approval pathway in early 2025.

Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS are key drug candidates with potential, though competition is significant. The company's $500 million capital raise supports its aggressive R&D investment, providing a runway for developing its pipeline.

Launched on 06/16/2006, the WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) is a smart beta exchange traded fund offering broad exposure to the World ETFs category of the market.

The WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) was launched on 06/16/2006, and is a smart beta ETF that offers extensive coverage of the global market's World ETFs sector.

The WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) made its debut on 06/16/2006, and is a smart beta exchange traded fund that provides broad exposure to the World ETFs category of the market.

WisdomTree Global ex‐U.S. Quality Dividend Growth Fund ETF holds about 300 international dividend stocks with quality and earnings growth characteristics. The portfolio is well-diversified across sectors and countries, and direct exposure to China is moderate. DNL total return is great relative to peers, but this “dividend growth” ETF is not for dividend-growth investors.

The WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) made its debut on 06/16/2006, and is a smart beta exchange traded fund that provides broad exposure to the World ETFs category of the market.